{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:24:10Z","timestamp":1791404650199,"version":"4.3.3"},"reference-count":155,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:00:00Z","timestamp":1672963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Gene therapy is defined as the administration of genetic material to modify, manipulate gene expression or alter the properties of living cells for therapeutic purposes. Recent advances and improvements in this field have led to many breakthroughs in the treatment of various diseases. As a result, there has been an increasing interest in the use of these therapies to treat motor neuron diseases (MNDs), for which many potential molecular targets have been discovered. MNDs are neurodegenerative disorders that, in their most severe forms, can lead to respiratory failure and death, for instance, spinal muscular atrophy (SMA) or amyotrophic lateral sclerosis (ALS). Despite the fact that SMA has been known for many years, it is still one of the most common genetic diseases causing infant mortality. The introduction of drugs based on ASOs\u2014nusinersen; small molecules\u2014risdiplam; and replacement therapy (GRT)\u2014Zolgensma has shown a significant improvement in both event-free survival and the quality of life of patients after using these therapies in the available trial results. Although there is still no drug that would effectively alleviate the course of the disease in ALS, the experience gained from SMA gene therapy gives hope for a positive outcome of the efforts to produce an effective and safe drug. The aim of this review is to present current progress and prospects for the use of gene therapy in the treatment of both SMA and ALS.<\/jats:p>","DOI":"10.3390\/ijms24021130","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T01:36:17Z","timestamp":1673228177000},"page":"1130","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Gene Therapy in ALS and SMA: Advances, Challenges and Perspectives"],"prefix":"10.3390","volume":"24","author":[{"given":"Jan","family":"Lejman","sequence":"first","affiliation":[{"name":"Student Scientific Society, Independent Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9014-5171","authenticated-orcid":false,"given":"Kinga","family":"Panuciak","sequence":"additional","affiliation":[{"name":"Student Scientific Society, Independent Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Nowicka","sequence":"additional","affiliation":[{"name":"Student Scientific Society, Independent Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Mastalerczyk","sequence":"additional","affiliation":[{"name":"Student Scientific Society, Independent Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Wojciechowska","sequence":"additional","affiliation":[{"name":"Independent Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8760-0775","authenticated-orcid":false,"given":"Monika","family":"Lejman","sequence":"additional","affiliation":[{"name":"Independent Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3389\/fnmol.2017.00405","article-title":"Motor Neuron Gene Therapy: Lessons from Spinal Muscular Atrophy for Amyotrophic Lateral Sclerosis","volume":"10","author":"Tosolini","year":"2017","journal-title":"Front. Mol. Neurosci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1002\/med.21705","article-title":"Modern Approaches in Gene Therapy of Motor Neuron Diseases","volume":"41","author":"Zakharova","year":"2021","journal-title":"Med. Res. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, Biodistribution and Cell Uptake of Antisense Oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Sardone, V., Zhou, H., Muntoni, F., Ferlini, A., and Falzarano, M.S. (2017). Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease. Molecules, 22.","DOI":"10.3390\/molecules22040563"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.drudis.2017.01.013","article-title":"Safety of Antisense Oligonucleotide and SiRNA-Based Therapeutics","volume":"22","author":"Chi","year":"2017","journal-title":"Drug Discov. Today"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.apsb.2020.01.015","article-title":"Gene Therapy for Neurodegenerative Disorders: Advances, Insights and Prospects","volume":"10","author":"Chen","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"931","DOI":"10.4103\/1673-5374.250570","article-title":"Characteristics and Advantages of Adeno-Associated Virus Vector-Mediated Gene Therapy for Neurodegenerative Diseases","volume":"14","author":"Qu","year":"2019","journal-title":"Neural Regen. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","article-title":"Spinal Muscular Atrophy","volume":"33","author":"Kolb","year":"2015","journal-title":"Neurol. Clin."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrn2670","article-title":"Spinal Muscular Atrophy: Why Do Low Levels of Survival Motor Neuron Protein Make Motor Neurons Sick?","volume":"10","author":"Burghes","year":"2009","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_10","first-page":"289","article-title":"Spinal Muscular Atrophy and a Model for Survival of Motor Neuron Protein Function in Axonal Ribonucleoprotein Complexes","volume":"48","author":"Rossoll","year":"2009","journal-title":"Results Probl. Cell Differ."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s12035-013-8399-5","article-title":"Spinal Muscular Atrophy and the Antiapoptotic Role of Survival of Motor Neuron (SMN) Protein","volume":"47","author":"Anderton","year":"2013","journal-title":"Mol. Neurobiol."},{"key":"ref_12","first-page":"289","article-title":"Rdzeniowy Zanik Mi\u0119\u015bni\u2014Deficyt Bia\u0142ka SMN [Spinal Muscular Atrophy: SMN Protein Deficiency]","volume":"35","year":"2001","journal-title":"Neurol. Neurochir. Pol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1093\/hmg\/ddaa145","article-title":"Altered Bone Development with Impaired Cartilage Formation Precedes Neuromuscular Symptoms in Spinal Muscular Atrophy","volume":"29","author":"Hensel","year":"2020","journal-title":"Hum. Mol. Genet."},{"key":"ref_14","first-page":"103","article-title":"Phenotype Modifiers of Spinal Muscular Atrophy: The Number of SMN2 Gene Copies, Deletion in the NAIP Gene and Probably Gender Influence the Course of the Disease","volume":"56","author":"Milewski","year":"2009","journal-title":"Acta Biochim. Pol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Chen, T.H. (2020). New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093297"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/978-3-319-89689-2_2","article-title":"Mechanism of Splicing Regulation of Spinal Muscular Atrophy Genes","volume":"20","author":"Singh","year":"2018","journal-title":"Adv. Neurobiol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Lejman, J., Zieli\u0144ski, G., Gawda, P., and Lejman, M. (2021). Alternative Splicing Role in New Therapies of Spinal Muscular Atrophy. Genes, 12.","DOI":"10.3390\/genes12091346"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/ana.24549","article-title":"Vascular Defects and Spinal Cord Hypoxia in Spinal Muscular Atrophy","volume":"79","author":"Somers","year":"2016","journal-title":"Ann. Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/emboj.2010.19","article-title":"The Splicing Regulator Sam68 Binds to a Novel Exonic Splicing Silencer and Functions in SMN2 Alternative Splicing in Spinal Muscular Atrophy","volume":"29","author":"Pedrotti","year":"2010","journal-title":"EMBO J."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Wee, C.D., Havens, M.A., Jodelka, F.M., and Hastings, M.L. (2014). Targeting SR Proteins Improves SMN Expression in Spinal Muscular Atrophy Cells. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0115205"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.biopha.2017.01.104","article-title":"Securinine Enhances SMN2 Exon 7 Inclusion in Spinal Muscular Atrophy Cells","volume":"88","author":"Chen","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41467-018-04110-1","article-title":"Targeting RNA Structure in SMN2 Reverses Spinal Muscular Atrophy Molecular Phenotypes","volume":"9","author":"Tessaro","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_23","first-page":"61","article-title":"Nusinersen: A Treatment for Spinal Muscular Atrophy","volume":"53","author":"Claborn","year":"2019","journal-title":"Ann. Pharm."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13023-020-01356-1","article-title":"Longitudinal Natural History of Type i Spinal Muscular Atrophy: A Critical Review","volume":"15","author":"Mercuri","year":"2020","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.nmd.2005.03.004","article-title":"A Motor Function Measure for Neuromuscular Diseases. Construction and Validation Study","volume":"15","author":"Payan","year":"2005","journal-title":"Neuromuscul. Disord."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Ramsey, D., Scoto, M., Mayhew, A., Main, M., Mazzone, E.S., Montes, J., de Sanctis, R., Young, S.D., Salazar, R., and Glanzman, A.M. (2017). Revised Hammersmith Scale for Spinal Muscular Atrophy: A SMA Specific Clinical Outcome Assessment Tool. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0172346"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/humu.24149","article-title":"Identification of SRSF10 as a Regulator of SMN2 ISS-N1","volume":"42","author":"Frederiksen","year":"2021","journal-title":"Hum. Mutat."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Messina, S., and Sframeli, M. (2020). New Treatments in Spinal Muscular Atrophy: Positive Results and New Challenges. J. Clin. Med., 9.","DOI":"10.3390\/jcm9072222"},{"key":"ref_29","first-page":"S3","article-title":"Gene Therapy for Spinal Muscular Atrophy: An Emerging Treatment Option for a Devastating Disease","volume":"24","author":"Rao","year":"2018","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of Infantile-Onset Spinal Muscular Atrophy with Nusinersen: A Phase 2, Open-Label, Dose-Escalation Study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"key":"ref_31","unstructured":"(2022, December 20). A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants with Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02386553."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/mus.25430","article-title":"Revised Upper Limb Module for Spinal Muscular Atrophy: Development of a New Module","volume":"55","author":"Mazzone","year":"2017","journal-title":"Muscle Nerve"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Bonanno, S., Marcuzzo, S., Malacarne, C., Giagnorio, E., Masson, R., Zanin, R., Arnoldi, M.T., Andreetta, F., Simoncini, O., and Venerando, A. (2020). Circulating MyomiRs as Potential Biomarkers to Monitor Response to Nusinersen in Pediatric SMA Patients. Biomedicines, 8.","DOI":"10.3390\/biomedicines8020021"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3389\/fncel.2022.982760","article-title":"Identification of a Cytokine Profile in Serum and Cerebrospinal Fluid of Pediatric and Adult Spinal Muscular Atrophy Patients and Its Modulation upon Nusinersen Treatment","volume":"16","author":"Bonanno","year":"2022","journal-title":"Front. Cell. Neurosci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1146\/annurev-virology-031413-085355","article-title":"AAV-Mediated Gene Therapy for Research and Therapeutic Purposes","volume":"1","author":"Samulski","year":"2014","journal-title":"Annu. Rev. Virol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.coviro.2016.08.004","article-title":"Adeno-Associated Virus and Lentivirus Vectors: A Refined Toolkit for the Central Nervous System","volume":"21","author":"Blessing","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s11689-018-9234-0","article-title":"Recent Progress and Considerations for AAV Gene Therapies Targeting the Central Nervous System","volume":"10","author":"Lykken","year":"2018","journal-title":"J. Neurodev. Disord."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"517","DOI":"10.4155\/tde.10.50","article-title":"Viral Vectors and Delivery Strategies for CNS Gene Therapy","volume":"1","author":"Gray","year":"2010","journal-title":"Ther. Deliv."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1113\/expphysiol.2004.028159","article-title":"Promoters and Serotypes: Targeting of Adeno-Associated Virus Vectors for Gene Transfer in the Rat Central Nervous System in Vitro and in Vivo","volume":"90","author":"Shevtsova","year":"2005","journal-title":"Exp. Physiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/gt.2015.112","article-title":"Healthy and Diseased Corticospinal Motor Neurons Are Selectively Transduced upon Direct AAV2-2 Injection into the Motor Cortex","volume":"23","author":"Jara","year":"2016","journal-title":"Gene Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging Issues in AAV-Mediated In Vivo Gene Therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/1061186X.2019.1630415","article-title":"Gene Therapy for Neurological Disorders: Challenges and Recent Advancements","volume":"28","author":"Pena","year":"2020","journal-title":"J. Drug Target."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4103\/ijabmr.IJABMR_190_19","article-title":"Onasemnogene Abeparvovec for Spinal Muscular Atrophy: The Costlier Drug Ever","volume":"9","author":"Mahajan","year":"2019","journal-title":"Int. J. Appl. Basic Med. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene Abeparvovec Gene Therapy for Symptomatic Infantile-Onset Spinal Muscular Atrophy in Patients with Two Copies of SMN2 (STR1VE): An Open-Label, Single-Arm, Multicentre, Phase 3 Trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pediatrneurol.2019.06.007","article-title":"From Clinical Trials to Clinical Practice: Practical Considerations for Gene Replacement Therapy in SMA Type 1","volume":"100","author":"Mendell","year":"2019","journal-title":"Pediatr. Neurol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/mt.2014.210","article-title":"Improving Single Injection CSF Delivery of AAV9-Mediated Gene Therapy for SMA: A Dose-Response Study in Mice and Nonhuman Primates","volume":"23","author":"Meyer","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3233\/JND-200593","article-title":"Safety Monitoring of Gene Therapy for Spinal Muscular Atrophy with Onasemnogene Abeparvovec\u2014A Single Centre Experience","volume":"8","author":"Friese","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/s41593-021-00827-3","article-title":"Gain of Toxic Function by Long-Term AAV9-Mediated SMN Overexpression in the Sensorimotor Circuit","volume":"24","author":"Tattoli","year":"2021","journal-title":"Nat. Neurosci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s40265-020-01410-z","article-title":"Risdiplam: First Approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"ref_53","unstructured":"FDA, and CDER (2022, August 24). Highlights of Prescribing Information: EVRYSDI (Risdisplam), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/213535s003s005lbl.pdf."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/s41467-017-01559-4","article-title":"Binding to SMN2 Pre-MRNA-Protein Complex Elicits Specificity for Small Molecule Splicing Modifiers","volume":"8","author":"Sivaramakrishnan","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_55","unstructured":"FDA Genentech Inc. (2023, January 05). EvrysdiTM (Risdiplam): US Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/213535s003s005lbl.pdf."},{"key":"ref_56","first-page":"E4604","article-title":"Mechanistic Studies of a Small-Molecule Modulator of SMN2 Splicing","volume":"115","author":"Wang","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e00447","DOI":"10.1002\/prp2.447","article-title":"Risdiplam Distributes and Increases SMN Protein in Both the Central Nervous System and Peripheral Organs","volume":"6","author":"Poirier","year":"2018","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1016\/j.nmd.2019.06.515","article-title":"P.353FIREFISH Part 1: 16-Month Safety and Exploratory Outcomes of Risdiplam (RG7916) Treatment in Infants with Type 1 Spinal Muscular Atrophy","volume":"29","author":"Baranello","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ana.25101","article-title":"Natural History of Infantile-Onset Spinal Muscular Atrophy","volume":"82","author":"Kolb","year":"2017","journal-title":"Ann. Neurol."},{"key":"ref_60","first-page":"117","article-title":"FIREFISH Part 2: Efficacy and Safety of Risdiplam (RG7916) in Infants with Type 1 Spinal Muscular Atrophy (SMA)","volume":"56","author":"Servais","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_61","unstructured":"(2022, December 22). PTC Therapeutics Announces 2-Year Data from Part 1 of SUNFISH and New Data from JEWELFISH Trials for Risdiplam in Patients with Spinal Muscular Atrophy|PTC Therapeutics, Inc. Available online: https:\/\/ir.ptcbio.com\/news-releases\/news-release-details\/ptc-therapeutics-announces-2-year-data-part-1-sunfish-and-new."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Mercuri, E., Barisic, N., Boespflug-Tanguy, O., Deconinck, N., Kostera-Pruszczyk, A., Masson, R., Mazzone, E., Nascimento, A., Saito, K., and Vlodavets, D. (2022, August 24). SUNFISH Part 2: Efficacy and Safety of Risdiplam (RG7916) in Patients with Type 2 or Non-Ambulant Type 3 Spinal Muscular Atrophy (SMA) (1260). Neurology, Available online: https:\/\/n.neurology.org\/content\/94\/15_Supplement\/1260.","DOI":"10.1212\/WNL.94.15_supplement.1260"},{"key":"ref_63","unstructured":"Chiriboga, C.A., Mercuri, E., Fischer, D., Kraus, D., Yeung, W.Y., Kletzl, H., Gerber, M., Cleary, Y., Gorni, K., and Khwaja, O. (2022, August 24). JEWELFISH: Risdiplam (RG7916) Increases SMN Protein in Non-Na\u00efve Patients with SMA. Available online: https:\/\/medically.roche.com\/content\/dam\/pdmahub\/non-restricted\/neurology\/wms-2018\/WMS_2018_JEWELFISH_risdiplam_poster_Chiriboga.pdf."},{"key":"ref_64","unstructured":"Finkel, R.S., Al-Muhaizea, M., Farrar, M.A., Nelson, L., Prufer, A., Servais, L., Wang, Y., Zanoteli, E., Palfreeman, L., and El-Khairi, M. (2023, January 19\u201322). RAINBOWFISH: A Study of Risdiplam in Newborns with Presymptomatic Spinal Muscular Atrophy (SMA). Proceedings of the MDA Clinical & Scientific Conference, Dallas, TX, USA. Available online: https:\/\/www.mdaconference.org\/abstract-library\/rainbowfish-a-study-of-risdiplam-in-newborns-with-presymptomatic-spinal-muscular-atrophy-sma\/."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpn.2022.04.006","article-title":"Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data","volume":"39","author":"Erdos","year":"2022","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"10067","DOI":"10.1021\/acs.jmedchem.6b00670","article-title":"Small Molecules in Development for the Treatment of Spinal Muscular Atrophy","volume":"59","author":"Calder","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_67","first-page":"S147","article-title":"273Serum Neurofilament Light Chain in Type 1 Spinal Muscular Atrophy: 30 Months Data from First Part of a Branaplam Phase II Study","volume":"29","author":"Peters","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.neuron.2016.11.033","article-title":"The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular Atrophy","volume":"93","author":"Ramos","year":"2017","journal-title":"Neuron"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"10962","DOI":"10.1073\/pnas.1605731113","article-title":"Systemic Peptide-Mediated Oligonucleotide Therapy Improves Long-Term Survival in Spinal Muscular Atrophy","volume":"113","author":"Hammond","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ajhg.2019.05.008","article-title":"NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen Further Ameliorates Spinal Muscular Atrophy in Mice","volume":"105","author":"Schneider","year":"2019","journal-title":"Am. J. Hum. Genet."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/hmg\/dds540","article-title":"Plastin 3 Ameliorates Spinal Muscular Atrophy via Delayed Axon Pruning and Improves Neuromuscular Junction Functionality","volume":"22","author":"Ackermann","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1126\/science.1155085","article-title":"Plastin 3 Is a Protective Modifier of Autosomal Recessive Spinal Muscular Atrophy","volume":"320","author":"Oprea","year":"2008","journal-title":"Science"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1093\/hmg\/dds102","article-title":"The Zinc Finger Protein ZPR1 Is a Potential Modifier of Spinal Muscular Atrophy","volume":"21","author":"Ahmad","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"216","DOI":"10.15585\/mmwr.mm6707a3","article-title":"Prevalence of Amyotrophic Lateral Sclerosis\u2014United States, 2014","volume":"67","author":"Mehta","year":"2019","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_75","first-page":"57","article-title":"Variation in Worldwide Incidence of Amyotrophic Lateral Sclerosis: A Meta-Analysis","volume":"46","author":"Marin","year":"2017","journal-title":"Int. J. Epidemiol."},{"key":"ref_76","first-page":"S320","article-title":"Amyotrophic Lateral Sclerosis: Disease State Overview","volume":"24","author":"Hulisz","year":"2018","journal-title":"Am. J. Manag. Care"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/med.21528","article-title":"Riluzole and Edaravone: A Tale of Two Amyotrophic Lateral Sclerosis Drugs","volume":"39","author":"Jaiswal","year":"2019","journal-title":"Med. Res. Rev."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.chest.2018.06.035","article-title":"Respiratory Failure in Amyotrophic Lateral Sclerosis","volume":"155","author":"Niedermeyer","year":"2019","journal-title":"Chest"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Cappella, M., Ciotti, C., Cohen-Tannoudji, M., and Biferi, M.G. (2019). Gene Therapy for ALS\u2014A Perspective. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20184388"},{"key":"ref_80","unstructured":"FDA, and CDER (2022, August 24). Highlights of Prescribing Information: RILUTEK, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/020599s017lbl.pdf."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.37765\/ajmc.2020.88483","article-title":"Overview of Current and Emerging Therapies for Amyotrophic Lateral Sclerosis","volume":"26","author":"Chen","year":"2020","journal-title":"Am. J. Manag. Care"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1080\/21678421.2021.1874992","article-title":"Effect of Riluzole on Weight in Short-Term and Long-Term Survivors of Amyotrophic Lateral Sclerosis","volume":"22","author":"Thakor","year":"2021","journal-title":"Amyotroph. Lateral Scler. Front. Degener."},{"key":"ref_83","unstructured":"(2022, December 22). Safety Study of Oral Edaravone Administered in Subjects with ALS, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04165824."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/17482960600881870","article-title":"Investigation of the Therapeutic Effects of Edaravone, a Free Radical Scavenger, on Amyotrophic Lateral Sclerosis (Phase II Study)","volume":"7","author":"Yoshino","year":"2006","journal-title":"Amyotroph. Lateral Scler."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Genge, A., Pattee, G.L., Sobue, G., Aoki, M., Yoshino, H., Couratier, P., Lunetta, C., Petri, S., Selness, D., and Bidani, S. Oral Edaravone Demonstrated a Favorable Safety Profile in Patients with Amyotrophic Lateral Sclerosis after 48\u2009Weeks of Treatment. Muscle Nerve, 2022.","DOI":"10.1002\/mus.27768"},{"key":"ref_86","first-page":"818","article-title":"RNA-Binding Proteins in Amyotrophic Lateral Sclerosis","volume":"41","author":"Zhao","year":"2018","journal-title":"Moleucles Cells"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3389\/fneur.2019.00527","article-title":"Structural Properties and Interaction Partners of Familial ALS-Associated SOD1 Mutants","volume":"10","author":"Huai","year":"2019","journal-title":"Front. Neurol."},{"key":"ref_88","first-page":"1891","article-title":"SOD1 Mutation Spectrum and Natural History of ALS Patients in a 15-Year Cohort in Southeastern China","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Genet."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jbior.2015.10.006","article-title":"SOD1 in Neurotoxicity and Its Controversial Roles in SOD1 Mutation-Negative ALS","volume":"60","author":"Hayashi","year":"2016","journal-title":"Adv. Biol. Regul."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3389\/fncel.2021.653688","article-title":"The Role of Mitochondrial Dysfunction and ER Stress in TDP-43 and C9ORF72 ALS","volume":"15","author":"Dafinca","year":"2021","journal-title":"Front. Cell Neurosci."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/jnc.15255","article-title":"Cellular and Physiological Functions of C9ORF72 and Implications for ALS\/FTD","volume":"157","author":"Pang","year":"2021","journal-title":"J. Neurochem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neuron.2011.09.011","article-title":"Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS","volume":"72","author":"Mackenzie","year":"2011","journal-title":"Neuron"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3389\/fneur.2019.00578","article-title":"Biological Significance of MicroRNA Biomarkers in ALS-Innocent Bystanders or Disease Culprits?","volume":"10","author":"Foggin","year":"2019","journal-title":"Front. Neurol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/ana.20453","article-title":"Virus-Delivered Small RNA Silencing Sustains Strength in Amyotrophic Lateral Sclerosis","volume":"57","author":"Miller","year":"2005","journal-title":"Ann. Neurol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nm1205","article-title":"Silencing Mutant SOD1 Using RNAi Protects against Neurodegeneration and Extends Survival in an ALS Model","volume":"11","author":"Ralph","year":"2005","journal-title":"Nat. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nm1207","article-title":"Lentiviral-Mediated Silencing of SOD1 through RNA Interference Retards Disease Onset and Progression in a Mouse Model of ALS","volume":"11","author":"Raoul","year":"2005","journal-title":"Nat. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1038\/mt.2013.211","article-title":"Therapeutic AAV9-Mediated Suppression of Mutant SOD1 Slows Disease Progression and Extends Survival in Models of Inherited ALS","volume":"21","author":"Foust","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/hmg\/ddt454","article-title":"Widespread Spinal Cord Transduction by Intrathecal Injection of RAAV Delivers Efficacious RNAi Therapy for Amyotrophic Lateral Sclerosis","volume":"23","author":"Wang","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00221-009-1742-4","article-title":"Retrogradely Transported SiRNA Silences Human Mutant SOD1 in Spinal Cord Motor Neurons","volume":"195","author":"Rizvanov","year":"2009","journal-title":"Exp. Brain Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1089\/hum.2015.122","article-title":"Therapeutic RAAVrh10 Mediated SOD1 Silencing in Adult SOD1(G93A) Mice and Nonhuman Primates","volume":"27","author":"Borel","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.ymthe.2017.05.017","article-title":"A New AAV10-U7-Mediated Gene Therapy Prolongs Survival and Restores Function in an ALS Mouse Model","volume":"25","author":"Biferi","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1021\/acs.molpharmaceut.1c00297","article-title":"Non-Viral Vector-Mediated Gene Therapy for ALS: Challenges and Future Perspectives","volume":"18","author":"Ediriweera","year":"2021","journal-title":"Mol. Pharm."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1172\/JCI25424","article-title":"Antisense Oligonucleotide Therapy for Neurodegenerative Disease","volume":"116","author":"Smith","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","article-title":"An Antisense Oligonucleotide against SOD1 Delivered Intrathecally for Patients with SOD1 Familial Amyotrophic Lateral Sclerosis: A Phase 1, Randomised, First-in-Man Study","volume":"12","author":"Miller","year":"2013","journal-title":"Lancet Neurol."},{"key":"ref_105","unstructured":"(2022, December 22). Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations, Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01041222."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2003715","article-title":"Phase 1\u20132 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS","volume":"383","author":"Miller","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_108","unstructured":"(2022, December 22). Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis | Biogen. Available online: https:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-and-ionis-announce-topline-phase-1-study-results."},{"key":"ref_109","unstructured":"(2022, December 22). An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults with Inherited Amyotrophic Lateral Sclerosis (ALS), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02623699."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.neuron.2013.10.015","article-title":"RNA Toxicity from the ALS\/FTD C9ORF72 Expansion Is Mitigated by Antisense Intervention","volume":"80","author":"Donnelly","year":"2013","journal-title":"Neuron"},{"key":"ref_111","first-page":"E4530","article-title":"Targeted Degradation of Sense and Antisense C9orf72 RNA Foci as Therapy for ALS and Frontotemporal Degeneration","volume":"110","author":"Baughn","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"208ra149","DOI":"10.1126\/scitranslmed.3007529","article-title":"Targeting RNA Foci in IPSC-Derived Motor Neurons from ALS Patients with a C9ORF72 Repeat Expansion","volume":"5","author":"Sareen","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.neuron.2016.04.006","article-title":"Gain of Toxicity from ALS\/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs","volume":"90","author":"Jiang","year":"2016","journal-title":"Neuron"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/WCO.0000000000000984","article-title":"Therapeutic Strategies for C9orf72 Amyotrophic Lateral Sclerosis and Frontotemporal Dementia","volume":"34","author":"Hautbergue","year":"2021","journal-title":"Curr. Opin. Neurol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/s41467-021-21112-8","article-title":"Variant-Selective Stereopure Oligonucleotides Protect against Pathologies Associated with C9orf72-Repeat Expansion in Preclinical Models","volume":"12","author":"Liu","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Arnold, C. Tailored Treatment for ALS Poised to Move Ahead. Nat. Med., 2019.","DOI":"10.1038\/d41591-019-00013-w"},{"key":"ref_117","unstructured":"(2022, December 22). A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants with Fused in Sarcoma Mutations (FUS-ALS), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04768972."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.molmed.2022.02.006","article-title":"InFUSing Antisense Oligonucleotides for Treating ALS","volume":"28","author":"Codron","year":"2022","journal-title":"Trends Mol. Med."},{"key":"ref_119","unstructured":"(2022, December 22). Ionis Pipeline: Antisense Drugs for a Broad Range of Diseases. Available online: https:\/\/www.ionispharma.com\/ionis-innovation\/pipeline\/."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nature22038","article-title":"Therapeutic Reduction of Ataxin-2 Extends Lifespan and Reduces Pathology in TDP-43 Mice","volume":"544","author":"Becker","year":"2017","journal-title":"Nature"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/mt.2009.71","article-title":"Intravenous Administration of Self-Complementary AAV9 Enables Transgene Delivery to Adult Motor Neurons","volume":"17","author":"Duque","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.molmed.2015.06.001","article-title":"Gene Therapy for Neurodegenerative Diseases","volume":"21","author":"Boulis","year":"2015","journal-title":"Trends Mol. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.bbadis.2006.05.003","article-title":"Gene Therapy for ALS: Progress and Prospects","volume":"1762","author":"Azzouz","year":"2006","journal-title":"Biochim. Et Biophys. Acta (BBA)-Mol. Basis Dis."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00005-010-0063-4","article-title":"Lentiviral Vectors in Gene Therapy: Their Current Status and Future Potential","volume":"58","author":"Escors","year":"2010","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1128\/JVI.03376-13","article-title":"Enhanced Central Nervous System Transduction with Lentiviral Vectors Pseudotyped with RVG\/HIV-1gp41 Chimeric Envelope Glycoproteins","volume":"88","author":"Trabalza","year":"2014","journal-title":"J. Virol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00702-016-1674-7","article-title":"Genetic Manipulation of Specific Neural Circuits by Use of a Viral Vector System","volume":"125","author":"Kobayashi","year":"2018","journal-title":"J. Neural. Transm."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neuropharm.2016.02.013","article-title":"Viral Vectors for Therapy of Neurologic Diseases","volume":"120","author":"Choudhury","year":"2017","journal-title":"Neuropharmacology"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/978-1-4939-3271-9_24","article-title":"Ex Vivo Gene Therapy Using Human Mesenchymal Stem Cells to Deliver Growth Factors in the Skeletal Muscle of a Familial ALS Rat Model","volume":"1382","author":"Suzuki","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.omtn.2018.04.015","article-title":"Translating SOD1 Gene Silencing toward the Clinic: A Highly Efficacious, Off-Target-Free, and Biomarker-Supported Strategy for FALS","volume":"12","author":"Iannitti","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_130","unstructured":"(2022, December 22). AveXis, ALS Gene Therapy AVXS-301 to Be Bought by Novartis for $8.7B. Available online: https:\/\/alsnewstoday.com\/news\/avexis-and-als-therapy-avxs-301-to-be-acquired-novartis\/."},{"key":"ref_131","unstructured":"(2022, December 22). Statement from Novartis Gene Therapies: OAV301 Program for Familial ALS Caused by SOD1 Mutation\u2014Les Turner ALS Foundation. Available online: https:\/\/lesturnerals.org\/oav301-program-for-familial-als-caused-by-sod1-mutation-statement-from-novartis-gene-therapies\/."},{"key":"ref_132","unstructured":"(2022, December 22). Apic Bio Receives FDA Fast Track Designation for APB-102 | Apic Bio. Available online: https:\/\/apic-bio.com\/apic-bio-receives-fda-fast-track-designation-for-apb-102-for-the-treatment-of-patients-with-sod1-als\/."},{"key":"ref_133","unstructured":"(2022, December 22). APB-102 Gene Therapy for SOD1 ALS Wins FDA Fast Track Status. Available online: https:\/\/alsnewstoday.com\/news\/apb-102-gene-therapy-sod1-als-wins-fda-fast-track\/."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2005056","article-title":"SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS","volume":"383","author":"Mueller","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"880","DOI":"10.15252\/emmm.201607298","article-title":"DOK7 Gene Therapy Enhances Motor Activity and Life Span in ALS Model Mice","volume":"9","author":"Miyoshi","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neurobiolaging.2012.07.018","article-title":"Advancing Neurotrophic Factors as Treatments for Age-Related Neurodegenerative Diseases: Developing and Demonstrating \u201cClinical Proof-of-Concept\u201d for AAV-Neurturin (CERE-120) in Parkinson\u2019s Disease","volume":"34","author":"Bartus","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"ref_137","first-page":"61","article-title":"Trophic Factors as Modulators of Motor Neuron Physiology and Survival: Implications for ALS Therapy","volume":"8","author":"Tapia","year":"2014","journal-title":"Front. Cell. Neurosci."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"113091","DOI":"10.1016\/j.expneurol.2019.113091","article-title":"Focal and Dose-Dependent Neuroprotection in ALS Mice Following AAV2-Neurturin Delivery","volume":"323","author":"Gross","year":"2020","journal-title":"Exp. Neurol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s12035-016-0335-z","article-title":"Intramuscular Delivery of ScAAV9-HIGF1 Prolongs Survival in the HSOD1G93A ALS Mouse Model via Upregulation of D-Amino Acid Oxidase","volume":"55","author":"Lin","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.gendis.2016.07.003","article-title":"CRISPR-Mediated Genome Editing and Human Diseases","volume":"3","author":"Cai","year":"2016","journal-title":"Genes Dis."},{"key":"ref_141","first-page":"625","article-title":"Focus: Genome Editing: Science and Bioethics of CRISPR-Cas9 Gene Editing: An Analysis Towards Separating Facts and Fiction","volume":"90","author":"Cribbs","year":"2017","journal-title":"Yale J. Biol. Med."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Karpe, Y., Chen, Z., and Li, X.J. (2021). Stem Cell Models and Gene Targeting for Human Motor Neuron Diseases. Pharmaceuticals, 14.","DOI":"10.3390\/ph14060565"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Yun, Y., and Ha, Y. (2020). CRISPR\/Cas9-Mediated Gene Correction to Understand ALS. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21113801"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrm.2017.48","article-title":"Non-Homologous DNA End Joining and Alternative Pathways to Double-Strand Break Repair","volume":"18","author":"Chang","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1016\/j.ymthe.2021.04.008","article-title":"Gene Therapy for ALS: A Review","volume":"29","author":"Amado","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ymthe.2021.04.003","article-title":"Novel Genome-Editing-Based Approaches to Treat Motor Neuron Diseases: Promises and Challenges","volume":"30","author":"Miccio","year":"2022","journal-title":"Mol. Ther."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/21655979.2017.1282018","article-title":"Cas9, Cpf1 and C2c1\/2\/3\u2015What\u2019s Next?","volume":"8","author":"Nakade","year":"2017","journal-title":"Bioengineered"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"eaar3952","DOI":"10.1126\/sciadv.aar3952","article-title":"In Vivo Genome Editing Improves Motor Function and Extends Survival in a Mouse Model of ALS","volume":"3","author":"Gaj","year":"2017","journal-title":"Sci. Adv."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41434-019-0116-1","article-title":"The Deletion of Mutant SOD1 via CRISPR\/Cas9\/SgRNA Prolongs Survival in an Amyotrophic Lateral Sclerosis Mouse Model","volume":"27","author":"Duan","year":"2019","journal-title":"Gene Ther."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s42003-021-01942-4","article-title":"Efficacy and Long-Term Safety of CRISPR\/Cas9 Genome Editing in the SOD1-Linked Mouse Models of ALS","volume":"4","author":"Deng","year":"2021","journal-title":"Commun. Biol."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Pribadi, M., Yang, Z., Kim, T.S., Swartz, E.W., Huang, A.Y., Chen, J.A., Dokuru, D., Baek, J., Gao, F., and Fua, A.T. (2016). CRISPR-Cas9 Targeted Deletion of the C9orf72 Repeat Expansion Mutation Corrects Cellular Phenotypes in Patient-Derived IPS Cells. bioRxiv, 051193.","DOI":"10.1101\/051193"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"9628","DOI":"10.1073\/pnas.1901313116","article-title":"Partial Inhibition of the Overactivated Ku80-Dependent DNA Repair Pathway Rescues Neurodegeneration in C9ORF72-ALS\/FTD","volume":"116","author":"Yang","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nbt.2623","article-title":"High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells","volume":"31","author":"Fu","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"7473","DOI":"10.1093\/nar\/gku402","article-title":"CRISPR\/Cas9 Systems Have off-Target Activity with Insertions or Deletions between Target DNA and Guide RNA Sequences","volume":"42","author":"Lin","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Kruminis-Kaszkiel, E., Juranek, J., Maksymowicz, W., and Wojtkiewicz, J. (2018). CRISPR\/Cas9 Technology as an Emerging Tool for Targeting Amyotrophic Lateral Sclerosis (ALS). Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19030906"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/2\/1130\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:01:27Z","timestamp":1760119287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/2\/1130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,6]]},"references-count":155,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["ijms24021130"],"URL":"https:\/\/doi.org\/10.3390\/ijms24021130","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,6]]}}}